CIA
SRPT icon

CSat Investment Advisory’s Sarepta Therapeutics SRPT Stock Holding History

CSat Investment Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-245
Closed -$34K – 904
2020
Q3 		$34K Buy
245
+32
+15% +$4.86K ﹤0.01% 737
2020
Q2 		$34K Sell
213
-358
-63% -$48.7K ﹤0.01% 727
2020
Q1 		$56K Buy
571
+94
+20% +$10.7K 0.01% 497
2019
Q4 		$62K Sell
477
-1,000
-68% -$101K 0.02% 549
2019
Q3 		$111K Buy
1,477
+267
+22% +$31.5K 0.03% 296
2019
Q2 		$184K Buy
+1,210
New +$147K 0.07% 199

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CSat Investment Advisory's SRPT Position: Q4 2020 in Review

CSat Investment Advisory sold out of Sarepta Therapeutics (SRPT) in Q4 2020, closing a stake of 245 shares — an estimated $34K sold.

CSat Investment Advisory first reported a position in SRPT in Q2 2019 and held it in 6 quarters. The position peaked at $184K in Q2 2019. 455 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

  • CSat Investment Advisory reported no remaining Sarepta Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 245 Sarepta Therapeutics shares in Q4 2020, an estimated $34K.
  • CSat Investment Advisory first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's Sarepta Therapeutics position peaked at $184K in Q2 2019.
  • 455 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.